On April 6, the U.S. Food and Drug Administration (FDA) announced it was allowing marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer genetic tests that the FDA as authorized. Read more
Advances in smart pump technology can improve patient safety and provide efficiencies in nursing care delivery. Join our webinar to learn more.
FDA allows marketing of consumer genetic tests
Share
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
